The estimated Net Worth of John Edward A.Edward St. Jo... is at least $3.52 million dollars as of 16 March 2016. John Jo owns over 833,332 units of Capricor Therapeutics Inc stock worth over $3,521,395 and over the last 10 years John sold CAPR stock worth over $0.
John has made over 3 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently John bought 833,332 units of CAPR stock worth $1,999,997 on 16 March 2016.
The largest trade John's ever made was buying 851,546 units of Capricor Therapeutics Inc stock on 21 January 2015 worth over $2,997,442. On average, John trades about 839,403 units every 140 days since 2015. As of 16 March 2016 John still owns at least 842,439 units of Capricor Therapeutics Inc stock.
You can see the complete history of John Jo stock trades at the bottom of the page.
John's mailing address filed with the SEC is 2560 LORD BALTIMORE DRIVE2560 LORD BALTIMORE DRIVE, , BALTIMOREBALTIMORE, MDMD, 2124421244.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... et Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: